» Articles » PMID: 38403442

Engineering CREB-activated Promoters for Adenosine-induced Gene Expression

Overview
Journal Biotechnol J
Specialty Biotechnology
Date 2024 Feb 25
PMID 38403442
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulation of the ribonucleoside, adenosine (ADO), triggers a cAMP response element binding protein (CREB)-mediated signaling pathway to suppress the function of immune cells in tumors. Here, we describe a collection of CREB-activated promoters that allow for strong and tunable ADO-induced gene expression in human cells. By optimizing number of CREB transcription factor binding sites and altering the core promoter region of CREB-based hybrid promoters, we created synthetic constructs that drive gene expression to higher levels than strong, endogenous mammalian promoters in the presence of ADO. These synthetic promoters are induced up to 47-fold by ADO, with minimal expression in their "off" state. We further determine that our CREB-based promoters are activated by other compounds that act as signaling analogs, and that combinatorial addition of ADO and these compounds has a synergistic impact on gene expression. Surprisingly, we also detail how background ADO degradation caused by the common cell culture media additive, fetal bovine serum (FBS), confounds experiments designed to determine ADO dose-responsiveness. We show that only after long-term heat deactivation of FBS can our synthetic promoters enable gene expression induction at physiologically relevant levels of ADO. Finally, we demonstrate that the strength of a CREB-based promoter is enhanced by incorporating other transcription factor binding sites.

Citing Articles

Promoter engineering with programmable upstream activating sequences in Aspergillus Niger cell factory.

Zheng X, Guo Y, Chen M, Lu Y, Du Y, Lei Y Microb Cell Fact. 2025; 24(1):20.

PMID: 39815338 PMC: 11734539. DOI: 10.1186/s12934-025-02642-y.


Applying metabolic control strategies to engineered T cell cancer therapies.

Fox A, Blazeck J Metab Eng. 2024; 86:250-261.

PMID: 39490640 PMC: 11611646. DOI: 10.1016/j.ymben.2024.10.009.

References
1.
Yamada M, Suzuki Y, Nagasaki S, Okuno H, Imayoshi I . Light Control of the Tet Gene Expression System in Mammalian Cells. Cell Rep. 2018; 25(2):487-500.e6. DOI: 10.1016/j.celrep.2018.09.026. View

2.
Craig J, Schumacher M, Mansoor S, Farrens D, Brennan R, Goodman R . Consensus and variant cAMP-regulated enhancers have distinct CREB-binding properties. J Biol Chem. 2001; 276(15):11719-28. DOI: 10.1074/jbc.M010263200. View

3.
He H, Liao Q, Zhao C, Zhu C, Feng M, Liu Z . Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. J Immunother Cancer. 2021; 9(10). PMC: 8496395. DOI: 10.1136/jitc-2021-002755. View

4.
Shen Y, Campbell R, Cote D, Paquet M . Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans. Front Neural Circuits. 2020; 14:41. PMC: 7373823. DOI: 10.3389/fncir.2020.00041. View

5.
Dutta R, Tiu B, Sakamoto K . CBP/p300 acetyltransferase activity in hematologic malignancies. Mol Genet Metab. 2016; 119(1-2):37-43. DOI: 10.1016/j.ymgme.2016.06.013. View